Hologic (HOLX) Stock Price
Hologic Price
Hologic (HOLX) Stock | ISIN US4364401012 | WKN 879100. The current Hologic stock price is 76.01 USD (2026). Revenue is 4.3 B USD. Net income is 1.02 B USD. The P/E ratio is 16.89. Market capitalization is 17.3 B USD. Hologic operates in the Health sector.
Over the last 19 years Hologic grew revenue by 12.2% annually, reaching 4.1 B USD. Earnings per share have grown at 12.1% per year over the last 19 years. For Hologic, the net margin of 13.8% is down versus 33.2% a few years ago.
Hologic stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Hologic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hologic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hologic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Hologic Price |
|---|
Hologic Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B USD) |
| NET INCOME (B USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 4.03 | 4.1 | 4.3 | 4.51 | 4.72 | 5.05 | 5.36 | 5.49 |
| – | 1.74 | 4.76 | 5.03 | 4.59 | 6.93 | 6.24 | 2.44 |
| 56.25 | 56.34 | 53.78 | 51.21 | 48.96 | 45.79 | 43.1 | 42.07 |
| 2.27 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 |
| 0.79 | 0.57 | 1.02 | 1.12 | 1.2 | 1.31 | 1.35 | 1.62 |
| 73.03 | -28.39 | 81.06 | 9.19 | 7.34 | 9.26 | 2.75 | 19.99 |
| 237.55 | 227.57 | 227.57 | 227.57 | 227.57 | 227.57 | 227.57 | 227.57 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Hologic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hologic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hologic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Hologic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hologic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Hologic stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic business model & stock analysis
Hologic SWOT Analysis
Strengths
Hologic Inc has several strengths that contribute to its success in the market. These strengths include:
- Strong brand reputation and recognition in the healthcare industry
- Wide range of innovative and high-quality medical devices and diagnostic solutions
- Strong financial performance and revenue growth
- Strong distribution network and global presence
- Commitment to research and development, leading to continuous product advancements
Weaknesses
Hologic Inc also has weaknesses that pose some challenges to the company. These weaknesses include:
- Relatively high production costs leading to higher product prices
- Dependence on a limited number of key suppliers for crucial components
- Limited diversification in terms of product portfolio
- Risk of regulatory changes affecting the healthcare industry
Opportunities
Despite the weaknesses, there are also opportunities for Hologic Inc to capitalize on. These opportunities include:
- Increased demand for advanced medical devices and diagnostic solutions
- Expansion into emerging markets with a growing healthcare sector
- Partnerships or acquisitions to enhance product portfolio diversification
- Technological advancements in the healthcare industry opening new possibilities
Threats
Hologic Inc faces certain threats that could negatively impact its business. These threats include:
- Intense competition from other major players in the medical device industry
- Changing regulatory environment and potential legal hurdles
- Economic downturn and reduced healthcare spending
- Emergence of substitute products or technologies
Hologic Segments
Hologic Revenue by Segment (1/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (2/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (3/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (4/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (5/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Segment (6/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Segment (7/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Region
3 Years
5 Years
Max
Details
Hologic Eulerpool Fair Value
Hologic historical P/E ratio, EBIT multiple, and P/S ratio
Hologic annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Hologic shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Earnings Estimates
Hologic Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | 1.08USD | 1.05 BUSD | 2026 Q2 |
| 2/4/2026 | 1.11USD | 1.09 BUSD | 2026 Q1 |
| 1/29/2026 | 1.11USD | 1.09 BUSD | 2026 Q1 |
| 11/7/2024 | 1.03USD | 997.29 MUSD | 2024 Q4 |
| 4/29/2024 | 1USD | 1.02 BUSD | 2024 Q2 |
| 1/30/2024 | 0.96USD | 995.56 MUSD | 2024 Q1 |
| 7/25/2023 | 0.89USD | 971.85 MUSD | 2023 Q3 |
| 4/25/2023 | 0.84USD | 937.4 MUSD | 2023 Q2 |
| 1/31/2023 | 0.88USD | 980.84 MUSD | 2023 Q1 |
| 10/31/2022 | 0.64USD | 876.81 MUSD | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Hologic stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Hologic shareholder structure
| % | Name |
|---|---|
11.41821% | |
5.6508% | |
4.33956% | |
4.14893% | |
3.69112% | |
2.60677% | |
2.60093% | |
2.4651% | |
2.274% | |
1.86643% |
Hologic Executives and Management Board
Mr. Stephen Macmillan
(61)Chairman of the Board, President, Chief Executive Officer · since 2013
Mr. Essex Mitchell
(46)Chief Operating Officer
Ms. Karleen Oberton
(56)Chief Financial Officer · since 2018
Mr. Jan Verstreken
(58)Group President - International
Dr. Jennifer Schneiders
(58)President - Diagnostic Solutions
Hologic Supply Chain
Frequently asked questions about Hologic
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
Hologic stock
Hologic Peer Group
Hologic Ticker
Hologic FIGI
All fundamentals and in-depth analysis of Hologic
Our stock analysis for Hologic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hologic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.